title: Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors.
abstract: We have developed a quantitative fluorescence cytometry (QFCM) method that can be used to measure BCL-2 family member proteins in cell lines and clinical samples. We described the validation of antibodies, methods development and application of the assay.
  
  
  
  We characterized and validated antibodies to BCL-2, BCL-XL, and MCL-1 in cell lines to confirm specificity for flow cytometry. Each protein was measured in a panel of leukemia/lymphoma cell lines and B-cells from chronic lymphocytic leukemia (CLL) patients treated with the BCL-2/BCL-XLinhibitor navitoclax. The cellular activity of various BCL-2 family member inhibitors alone and in combination was determined to demonstrate utility of our assay to correlate protein levels with efficacy.
  
  
  
  We identified antibodies that were highly specific for each protein. The expression profile in cell lines as determined by molecules of equivalent soluble fluorochrome was comparable to western blot. Using our assay, BCL-2, BCL-XL, and MCL-1 protein levels were shown to correlate with response to BCL-2 family inhibitors in vitro and could be measured in clinical samples.
  
  
  
  This method can quantify BCL-2 family members in a specific, highly reproducible and sensitive fashion, and requires fewer cells compared to western blot. It is particularly useful for identifying BCL-2, BCL-XL, and MCL-1 protein levels in a specific cell population within a heterogeneous population like those collected from CLL patients. These data show that our QFCM method can be used to facilitate the quantification and evaluation of biomarkers predictive of response in patients treated with BCL-2 family member inhibitors. © 2016 International Clinical Cytometry Society.
authors.affiliation: Research and Development, Oncology Discovery, AbbVie, Inc, 1 North Waukegan Rd, North Chicago, Illinois, 60064.
authors.forename: Morey L
authors.initials: ML
authors.lastname: Smith
authors.affiliation: Research and Development, Oncology Discovery, AbbVie, Inc, 1 North Waukegan Rd, North Chicago, Illinois, 60064.
authors.forename: Brenda
authors.initials: B
authors.lastname: Chyla
authors.affiliation: Research and Development, Oncology Discovery, AbbVie, Inc, 1 North Waukegan Rd, North Chicago, Illinois, 60064.
authors.forename: Evelyn
authors.initials: E
authors.lastname: McKeegan
authors.affiliation: Research and Development, Oncology Discovery, AbbVie, Inc, 1 North Waukegan Rd, North Chicago, Illinois, 60064.
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Tahir
mesh_terms: D000814:Aniline Compounds / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects / Q000473:pathology; D045744:Cell Line, Tumor / Q000166:cytology; D019008:Drug Resistance, Neoplasm / Q000276:immunology; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; C000595707:BCL2 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; C528561:navitoclax
keywords: ABT-199/GDC-0199; BCL-2; QFCM; chronic lymphocytic leukemia